Lonza and Clovis Oncology sign long-term manufacturing agreement to secure supply of rucaparib
First dedicated small-molecule manufacturing line to be constructed in Visp, Switzerland.
Lonza has entered into a long-term commercial supply agreement with Clovis Oncology for the manufacture of Clovis’s development-stage PARP inhibitor, rucaparib. The focus of the agreement is to provide Clovis with security of supply and the flexibility to react swiftly to changes in market demand scenarios. Both companies are strengthening their relationship after a successful collaboration on clinical manufacturing of the highly potent API.
Rucaparib is a candidate targeting various cancer types through the inhibition of DNA-repair enzyme poly-ADP ribose polymerase-1, 2 and 3 (PARP-1, -2 and -3). The FDA has granted the molecule Breakthrough Therapy Designation for monotherapy treatment of patients with advanced ovarian cancer with BRCA-mutated tumours and who have been treated with two or more chemotherapies.
Under the agreement with Clovis, Lonza will construct a new production train in Visp (Switzerland) that will be exclusively dedicated to the manufacture of rucaparib. With this agreement Lonza implements a new dedicated facility concept for small molecules using modern technologies, including extensive on-line analytical monitoring that is designed to facilitate real-time release testing. The dedicated train guarantees access to manufacturing capacity for Clovis and allows coverage of the full range of anticipated demand scenarios for commercial supply.
By the beginning of 2019, the new train should be completed and operationally qualified. Until the completion of the new train, Lonza will manufacture rucaparib in its existing facilities in Visp with dedicated access to capacity. The agreement represents a comprehensive supply strategy supporting the customers ongoing business needs through commercialization and ongoing market supply.
“We’re looking forward to further developing our relationship into a long and productive partnership with Clovis to supply this innovative medicine to cancer patients across the globe,” said Gordon Bates, Senior Vice President, Business Unit Head, Chemical and Microbial Manufacturing for Lonza.
“Rucaparib is a highly potent drug, where our expertise in safely handling and scaling highly potent compounds at clinical and commercial scale supported Clovis through to submission,” he added. “This latest agreement continues to demonstrate our flexibility in developing customized supply solution for accelerated approval breakthrough designation programs to support our customers as they meet some of the greatest challenges in patient treatment.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance